Wayne Ghesquiere

TL;DR: The C-WORTHY trial as mentioned in this paper was a randomized, open-label phase 2 trial of grazoprevir plus elbasvir with or without ribavirin in patients with hepatitis C virus (HCV) genotype 1 infection with baseline characteristics of poor response.

TL;DR: Twelve or 16 weeks of treatment with daclatasvir, in combination with peginterferon alfa-2a and ribavirin, is a well tolerated and effective therapy for patients with HCV genotype 2 or 3 infections.

TL;DR: FDV plus PegIFN/ RBV significantly increased SVR12 rates in HCV GT-1 patients in Europe and Japan compared with PegIFn/RBV alone and was well tolerated.

TL;DR: Even in this small cohort, the full clinical spectrum of acute Zika virus, including adverse fetal and neurologic outcomes are observed, suggesting that complications from Zika infection are underestimated by data arising exclusively from populations where Zika is endemic.

TL;DR: This analysis provides an epidemiologic framework for Canadian practitioners encountering prospective and returned travellers and confirms the importance of preventive measures and surveillance associated with travel to sub-Saharan Africa and India, particularly by travellers visiting friends or relatives.